Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic PatientsPRNewsWire • 06/15/20
Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B VaccinePRNewsWire • 05/18/20
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/10/20
Provention Bio: Discounted Price, Insider Buying, And Catalysts Frame The OpportunitySeeking Alpha • 03/30/20
Proventio Bio Pauses Clinical Trial Over Fears Surrounding the Coronavirus OutbreakThe Motley Fool • 03/18/20
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/12/20
Provention Bio: A Buy On Type 1 Diabetes Opportunity And Clear Path To ApprovalSeeking Alpha • 03/04/20
Here's Why Momentum Investors Will Love Provention Bio, Inc. (PRVB)Zacks Investment Research • 12/04/19
Provention Bio: The Time Is Right For Teplizumab - High Potential Upside, Low Valuation, Milestones ApproachingSeeking Alpha • 11/29/19
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/09/19
Provention Bio Is A Misunderstood Biotech With A Potential Quick Pathway To FDA Approval For Type 1 Diabetes TreatmentSeeking Alpha • 10/03/19